Erratum
Main text: After the publication of this work [1] an error was noticed in Fig. 8. In the SMAD2P465/467 panel, the images for MCF-7 and MDA MB 231 cells were accidentally duplicated. The corrected figure is shown below. We apologize for this error, which does not affect the findings or conclusions of the article.
Fig. 8.
JMJD6 expression affects SMAD phosphorylation. Immunoblots show that the level of total SMAD2/3, phosphorylated SMAD2 and phosphorylated SMAD3 are decreased in MCF-7 J1-OE clones, and increased in JMJD6 siRNA-mediated knock-down in MCF-7 and MDA-MB231. The numbers next to the SMAD2P/3P denote the expected sites of phosphorylation detected by the antibodies. N.S. denotes non-specific bands from the blots which indicate equal loading of the protein lysates
Footnotes
The online version of the original article can be found under doi:10.1186/bcr3200.
Reference
- 1.Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast cancer research: BCR. 2012;14(3):R85. doi: 10.1186/bcr3200. [DOI] [PMC free article] [PubMed] [Google Scholar]